Latham & Watkins Advises Novo Holdings on BBI Group Acquisition

Latham & Watkins advised Novo Holdings A/S, a leading global life sciences investor, on its acquisition of BBI Group, a leading supplier of products and services to the global diagnostics and life sciences industries, from Exponent for an enterprise value of over £400 million. Novo Holdings will be the majority shareholder of the company.

BBI Group provides critical reagents and immunoassay development, lateral flow development, diagnostic manufacturing services, and smartphone reader technologies to a global blue-chip customer base. The company's market-leading brand, BBI Solutions, provides a range of products, including antibodies, antigens, labels, complementary reagents, and point of care tests.

The Latham team was led in London by corporate partner Robbie McLaren, with associates Emily Cridland and Devdeep Ghosh. Advice on life science matters by was provided by associates Frances Stocks Allen, Sara Patel, Oliver Mobasser, Mihail Krepchev, Oscar Bjartell, Lorenzo Meusburger, and Luke Vaz.